title: [Fluorine-18 in radiopharmacy].
abstract: Positron emission tomography (PET) is a recent and expanding functional nuclear imaging technique. Its extensive development is related to the radiophysical properties fluorine 18 (18F) (weak energy of positron, sufficiently long physical half-life) and to the simple production and labeling procedures for 18F. [18F]fluorodesoxyglucose was the first licensed radiopharmaceutical in France in 1998. [18F]fluoroDOPA was registered in 2006. Introduction of automated chemistry modules enable development of new fluorinated tracers.
authors.affiliation: Service de Radiopharmacie-phamacie, CHU d'Avicenne, 125, route de Stalingrad, 93009 Bobigny cedex, France. virginie.de-beco@avc.aphp.fr
authors.forename: V
authors.initials: V
authors.lastname: de Beco
authors.forename: D
authors.initials: D
authors.lastname: Le Bars
authors.forename: J-M
authors.initials: JM
authors.lastname: Scherrmann
mesh_terms: D000818:Animals; D004298:Dopamine / Q000031:analogs & derivatives; D005462:Fluorine Radioisotopes / Q000737:chemistry*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000737:chemistry*
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C029253:6-fluorodopamine; D004298:Dopamine